Effects of curcumin for preventing restenosis in a hypercholesterolemic rabbit iliac artery stent model

Catheterization and Cardiovascular Interventions

Volumn 74, Issue 6, 2009, Pages 881-888

  Jang, Hyung Suk ^a   Nam, Hye Yeong ^b   Kim, Jeong Min ^a   Hahm, Dong Hoon ^a   Nam, So Hee ^b   Kim, Koung Li ^a   Joo, Jae Ryang ^b   Suh, Wonhee ^a   Park, Jong Sang ^b   Kim, Duk Kyung ^a   Gwon, Hyeon Cheol ^a  

^a Samsung Medical Center   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Curcumin; Drug eluting stent; Restenosis

Indexed keywords

CURCUMIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BARE METAL STENT; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFICACY; DRUG ELUTING STENT; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; GROWTH INHIBITION; HYPERCHOLESTEROLEMIA; ILIAC ARTERY; IN VIVO STUDY; LOW DRUG DOSE; MALE; MATERIAL COATING; NONHUMAN; RABBIT; RAT; RESTENOSIS; SCANNING ELECTRON MICROSCOPY;

ANGIOPLASTY, BALLOON; ANIMALS; ARTERIAL OCCLUSIVE DISEASES; CARDIOVASCULAR AGENTS; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COATED MATERIALS, BIOCOMPATIBLE; CONSTRICTION, PATHOLOGIC; CURCUMIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG-ELUTING STENTS; HYPERCHOLESTEROLEMIA; ILIAC ARTERY; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PLATELET-DERIVED GROWTH FACTOR; PROSTHESIS DESIGN; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; SURFACE PROPERTIES; TIME FACTORS;

EID: 73249133992     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.22047     Document Type: Article

References (24)

1. Hamon M, Bauters C, McFadden EP, Wernert N, Lablanche JM, Dupuis B, Bertrand ME. Restenosis after coronary angioplasty. Eur Heart J 1995;16 Suppl I:33-48.
2. Casterella PJ. Restenosis: An overview. Front Radiat Ther Oncol 2001;35:147-171.
3. El-Omar MM, Dangas G, Iakovou I, Mehran R. Update on instent restenosis. Curr Interv Cardiol Rep 2001;3:296-305.
4. Hoffmann R, Mintz GS. Coronary in-stent restenosis - predictors, treatment and prevention. Eur Heart J 2000;21:1739-1749.
5. Waugh J, Wagstaff AJ. The paclitaxel (TAXUS)-eluting stent: A review of its use in the management of de novo coronary artery lesions. Am J Cardiovasc Drugs 2004;4:257-268.
6. Degertekin M, Regar E, Tanabe K, Smits PC, van der Giessen WJ, et al. Sirolimus-eluting stent for treatment of complex instent restenosis: The first clinical experience. J Am Coll Cardiol 2003;41:184-189.
7. Tanabe K, Serruys PW, Grube E, Smits PC, Selbach G, et al. TAXUS III Trial: In-stent restenosis treated with stent-based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003;107:559-564.
8. Sousa JE, Costa MA, Sousa AGMR, Abizaid AC, Seixas AC, et al. Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries. Circulation 2003;107:381-383.
9. Lal B, Kapoor AK, Agrawal PK, Asthana OP, Srimal RC. Role of curcumin in idiopathic inflammatory orbital pseudotumours. Phytother Res 2000;14:443-447.
10. Lal B, Kapoor AK, Asthana OP, Agrawal PK, Prasad R, Kumar P, Srimal RC. Efficacy of curcumin in the management of chronic anterior uveitis. Phytother Res 1999;13:318-322.
11. Jiao Y, Wilkinson J IV, Di X, Wang W, Hatcher H, Kock ND, D'Agostino R Jr., Knovich MA, Torti FM, Torti SV. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood 2009;113:462-469.
12. Foryst-Ludwig A, Neumann M, Schneider-Brachert W, Naumann M. Curcumin blocks NF-κB and the motogenic response in Helicobacter pylori-infected epithelial cells. Biochem Biophys Res Commun 2004;316:1065-1072.
13. Goel A, Boland CR, Chauhan DP. Specific inhibition of cyclooxygenase-2 (COX-2) expression by dietary curcumin in HT-29 human colon cancer cells. Cancer Lett 2001;172:111-118.
14. Pan M-H, Lin-Shiau S-Y, Lin J-K. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IκB kinase and NFκB activation in macrophages. Biochem Pharmacol 2000; 60:1665-1676.
15. Swarnakar S, Ganguly K, Kundu P, Banerjee A, Maity P, Sharma AV. Curcumin regulates expression and activity of matrix metalloproteinases 9 and 2 during prevention and healing of indomethacin-induced gastric ulcer. J Biol Chem 2005;280:9409-9415.
16. Chen HW, Huang HC. Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells. Br J Pharmacol 1998;124:1029-1040.
17. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res 2001;21(4B):2895-2900.
18. Mehta K, Pantazis P, McQueen T, Aggarwal BB. Antiproliferative effect of curcumin (diferuloylmethane) against human breast tumor cell lines. Anticancer Drugs 1997;8:470-481.
19. Moragoda L, Jaszewski R, Majumdar AP. Curcumin induced modulation of cell cycle and apoptosis in gastric and colon cancer cells. Anticancer Res 2001;21(2A):873-878.
20. Singh AK, Sidhu GS, Deepa T, Maheshwari RK. Curcumin inhibits the proliferation and cell cycle progression of human umbilical vein endothelial cell. Cancer Lett 1996;107:109-115.
21. Schwartz RS, Huber KC, Murphy JG, Edwards WD, Camrud AR, Vlietstra RE, Holmes DR. Restenosis and the proportional neointimal response to coronary artery injury: Results in a porcine model. J Am Coll Cardiol 1992;19:267-274.
22. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, Mihalcsik L, Tespili M, Valsecchi O, Kolodgie FD. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: Should we be cautious? Circulation 2004;109:701-705.
23. Iakovou I, Schmidt T, Bonizzoni E, Ge L, Sangiorgi GM, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130.
24. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005;45: 2088-2092.